Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Gains from Sales and Divestitures (2023 - 2025)

Standard Biotools (LAB) has disclosed Gains from Sales and Divestitures for 2 consecutive years, with $383000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Gains from Sales and Divestitures rose 636.54% to $383000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $383000.0, a 636.54% increase, with the full-year FY2024 number at $383000.0, up 636.54% from a year prior.
  • Gains from Sales and Divestitures was $383000.0 for Q4 2024 at Standard Biotools, down from $4.0 million in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $4.0 million in Q3 2024 to a low of $52000.0 in Q4 2023.